Trimethoprim/sulfamethoxazole

Developed for: bacterial infectious disease
Investigated by: Andalusian Public Foundation for Health Research in Seville · Spanish Network for Research in Infectious Diseases

today NCT02795949 · Ph 3

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT02795949	Oct 2016 → Jan 2020	bacterial infectious disease	Andalusian Public Foundation for Health Research in Seville	Completed	Met primary

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Trimethoprim/sulfamethoxazole	“Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h” NCT02795949 ↗
Route	Intravenous	“Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h” NCT02795949 ↗